Breaking News, Trials & Filings

MHRA Approves Roche’s Tecentriq Subcutaneous with ENHANZE

Co-formulated with Halozyme's recombinant human hyaluronidase enzyme, rHuPH20, allowing for subcutaneous delivery.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

The Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain has approved Roche’s Tecentriq SC (atezolizumab) using Halozyme’s ENHANZE drug delivery technology. Tecentriq subcutaneous (SC) is co-formulated with Halozyme’s recombinant human hyaluronidase enzyme, rHuPH20, allowing for subcutaneous delivery, which takes approximately seven minutes, compared with 30-60 minutes for intravenous (IV) infusion. Tecentriq SC will be available to patients in Great B...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters